Medtronic's Guardian Connect continuous glucose monitoring system was approved by the FDA for diabetes patients ages 14 to 75 after a clinical trial showed that it accurately alerted patients about 98.5% of hypoglycemic events. The device uses an advanced glucose sensor to alert patients of potentially low or high glucose events and enables caregivers to monitor blood glucose levels of users in real time.
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.